Concomitant resistance and early-breast cancer: should we change treatment strategies?

摘要: The dynamics of disease recurrence shows a bimodal pattern with fairly broad dominant peak at about 1.5–2 years after surgery followed by second 5 years. Nowadays, this clinical is explained assuming that primary breast tumours as well their metastases have phases both arrested (tumour dormancy) and active Gompertzian growth. Tumour dormancy metastatic sites currently ascribed to biological particularities local tissue microenvironments inhibit the growth tumour cells. However, in some patients, appears also depend on direct interplay between those metastases, phenomenon called “concomitant resistance”. Concomitant resistance related three processes: concomitant immunity, tumour-induced angiogenesis athrepsia. can explain relapse cancer patients many other phenomena such better outcome among surgically treated during putative early luteal phase, or worse African-American premenopausal women. Any therapeutic interventions (even surgery) affect potential induce outcome. This should be taken into account when planning new treatment strategies.